Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $600.2 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 35.45% year-over-year to $600.2 million in Q1 2026; TTM through Mar 2026 was $600.2 million, a 35.45% increase from a year earlier, with the FY2025 full-year figure at $528.1 million, up 19.32% from the prior year.
• Total Non-Current Liabilities climbed to $600.2 million in Q1 2026 per MIRM's latest filing, from $528.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $600.2 million in Q1 2026 and bottomed at $36.3 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $413.1 million (2024), against an average of $355.3 million.
• Across the five-year window, Total Non-Current Liabilities tumbled 68.09% in 2022 and surged 569.02% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $206.3 million in 2022, then soared by 91.0% to $394.1 million in 2023, then increased by 12.31% to $442.6 million in 2024, then rose by 19.32% to $528.1 million in 2025, then rose by 13.64% to $600.2 million in 2026.
• Per Business Quant, the three latest MIRM Total Non-Current Liabilities figures stand at $600.2 million (Q1 2026), $528.1 million (Q4 2025), and $477.1 million (Q3 2025).